research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
Search
for
Sort by
Research
210-240 / 1000+ resultsresearch RAPID ALKALINIZATION FACTOR 22 is a key modulator of the root hair growth responses to fungal ethylene emissions in Arabidopsis
RALF22 is essential for root hair growth in response to fungal emissions in Arabidopsis.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
research Evaluation of Serum Irisin and Its Relation to Insulin Resistance in Patients with Androgenetic Alopecia
Lower serum irisin levels are linked to androgenetic alopecia but not to insulin resistance.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research Involvement of RIPK1 in Alopecia Areata
RIPK1 inhibitors might help prevent alopecia areata.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Near Infrared (NIR) Light Therapy of Eye Diseases: A Review
NIR light therapy may effectively treat eye diseases and improve brain function without side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Pinkie, the First Viable Germline Hypomorph Allele of Retinoid X Receptor Alpha, Reveals an Important Role for RXRa in Th2 Development.
RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research ABHRS news
The document cannot be understood or processed.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Infrared light returns hair to 'growing phase'
Infrared light therapy helps regrow hair.
research ISHRS Best Practices Survey Project MODULE: Anesthesia and Emergency SUMMARY ANALYSIS
research LEVERAGING MACHINE LEARNING METHODS IN PREDICTING AND ANALYZING THE ASSOCIATION BETWEEN DIETARY INFLAMMATORY INDEX AND ALOPECIA
Inflammatory diets may increase the risk and severity of alopecia areata.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Could red and near-infrared emitting fabric technology improve the severity of psoriasis, polymorphous light eruption, and alopecia areata?
Red and near-infrared light-emitting fabric may help improve psoriasis, PMLE, and alopecia areata.
research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research 504 A single-center retrospective study evaluating the efficacy of intravenous methylprednisolone pulse therapy for 113 patients with alopecia areata
Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research A retrospective analysis of efficacy and safety of intralesional triamcinolone injections in the treatment of frontal fibrosing alopecia either as monotherapy or as a concomitant therapy
Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.